Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 247973, 4 pages
http://dx.doi.org/10.1155/2012/247973
Research Article

B-Cell-Activating Factor Affects the Occurrence of Thyroid Autoimmunity in Chronic Hepatitis C Patients Treated with Interferon Alpha

1Fourth Department of Internal Medicine, Teikyo University Mizonokuchi Hospital, 3-8-3 Mizonokuchi, Kawasaki-shi, Kanagawa 213-8507, Japan
2Central Laboratory, Teikyo University Mizonokuchi Hospital, 3-8-3 Mizonokuchi, Kawasaki-shi, Kanagawa 213-8507, Japan
3Delta Clinic, 2-5-1 Kusunokidai, Tokorozawa-shi, Saitama 359-0037, Japan

Received 18 October 2011; Revised 25 November 2011; Accepted 25 November 2011

Academic Editor: Ana Lepique

Copyright © 2012 Yusuke Kajiyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. M. Pfeffer, C. A. Dinarello, R. B. Herberman et al., “Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons,” Cancer Research, vol. 58, no. 12, pp. 2489–2499, 1998. View at Google Scholar · View at Scopus
  2. M. W. Russo and M. W. Fried, “Side effects of therapy for chronic hepatitis C,” Gastroenterology, vol. 124, no. 6, pp. 1711–1719, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. F. Prummel and P. Laurberg, “Interferon-α and autoimmune thyroid disease,” Thyroid, vol. 13, no. 6, pp. 547–551, 2003. View at Google Scholar · View at Scopus
  4. L. K. Koh, F. S. Greenspan, and P. P. Yeo, “Interferon-α induced thyroid dysfunction: three clinical presentations and a review of the literature,” Thyroid, vol. 7, no. 6, pp. 891–896, 1997. View at Google Scholar · View at Scopus
  5. J. C. Mandac, S. Chaudhry, K. E. Sherman, and Y. Tomer, “The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification,” Hepatology, vol. 43, no. 4, pp. 661–672, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. P. A. Moore, O. Belvedere, A. Orr et al., “BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator,” Science, vol. 285, no. 5425, pp. 260–263, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. H. B. Shu, W. H. Hu, and H. Johnson, “TALL-1 is a novel member of the TNF family that is down-regulated by mitogens,” Journal of Leukocyte Biology, vol. 65, no. 5, pp. 680–683, 1999. View at Google Scholar · View at Scopus
  8. P. Schneider, F. Mackay, V. Steiner et al., “BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1747–1756, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Mukhopadhyay, J. Ni, Y. Zhai, G. L. Yu, and B. B. Aggarwal, “Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-jun NH,” Journal of Biological Chemistry, vol. 274, no. 23, pp. 15978–15981, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Gross, J. Johnston, S. Mudri et al., “TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease,” Nature, vol. 404, no. 6781, pp. 995–999, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. G. S. Cheema, V. Roschke, D. M. Hilbert, and W. Stohl, “Elevated serum B lymphcyte stimulator levels in patients with systemic immune-based rheumatic diseases,” Arthritis & Rheumatism, vol. 44, no. 6, pp. 1313–1319, 2001. View at Google Scholar
  12. W. Stohl, S. Metyas, S. M. Tan et al., “B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations,” Arthritis and Rheumatism, vol. 48, no. 12, pp. 3475–3486, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. Groom, S. L. Kalled, A. H. Cutler et al., “Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 59–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Zhang, V. Roschke, K. P. Baker et al., “Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus,” Journal of Immunology, vol. 166, no. 1, pp. 6–10, 2001. View at Google Scholar · View at Scopus
  15. X. Mariette, S. Roux, J. Zhang et al., “The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome,” Annals of the Rheumatic Diseases, vol. 62, no. 2, pp. 168–171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. O. Pers, C. Daridon, V. Devauchelle et al., “BAFF overexpression is associated with autoantibody production in autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 1050, pp. 34–39, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. Y. Tomer and R. Villanueva, “Hepatitis C and thyroid autoimmunity: is there a link?” American Journal of Medicine, vol. 117, no. 1, pp. 60–61, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. Antonelli, C. Ferri, A. Pampana et al., “Thyroid disorders in chronic hepatitis C,” American Journal of Medicine, vol. 117, no. 1, pp. 10–13, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. Y. Tomer and F. Menconi, “Interferon induced thyroiditis,” Best Practice and Research, vol. 23, no. 6, pp. 703–712, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. Y. Tomer, J. T. Blackard, and N. Akeno, “Interferon alpha treatment and thyroid dysfunction,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 4, pp. 1051–1066, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. Y. Izumi, A. Komori, Y. Yasunaga et al., “Rheumatoid arthritis following a treatment with IFN-alpha/ribavirin against HCV infection,” Internal Medicine, vol. 50, no. 9, pp. 1065–1068, 2011. View at Publisher · View at Google Scholar
  22. S. L. Kalled, C. Ambrose, and Y. M. Hsu, “BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders,” Expert Opinion on Therapeutic Targets, vol. 7, no. 1, pp. 115–123, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. I. Moisini and A. Davidson, “BAFF: a local and systemic target in autoimmune diseases,” Clinical and Experimental Immunology, vol. 158, no. 2, pp. 155–163, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus